Drug Price Regulation, B.C. Reg. 344/2012

Section 1

Definitions

Cite as Drug Price Regulation, B.C. Reg. 344/2012, s. 1 · last amended March 1, 2026 · read from BC Laws on November 17, 2026

The text

(1) In this regulation: “Act” means the Pharmaceutical Services Act; “brand drug” means a drug (a) for which the first notice of compliance has been issued under section C.08.004 or C.08.004.01 of the Food and Drug Regulations (Canada), C.R.C., c. 870, in respect of all 3 of the following: (i) a particular active ingredient or combination of particular active ingredients; (ii) strength; (iii) dosage form, and (b) that, before the issuance of any subsequent notice of compliance for another drug having the same active ingredient or combination of active ingredients, is or was marketed in Canada by (i) the drug's innovator, or (ii) a person acting under a licence granted by the drug's innovator; “generic drug” means a drug having the same active ingredient or combination of active ingredients as a brand drug; “generic drug inclusion or exclusion” means the inclusion of at least one additional generic drug in, or the exclusion of at least one generic drug from, an LCA category; “high cost drug” means a high cost drug designated under section 7 (1) [high cost drugs]; “LCA category” means a category of drugs established under section 3 (1) (a) [LCA program]; “LCA drug comparator” means the drug designated under section 3 (1) (c) as the LCA drug comparator for an LCA category; “LCA program” means the low cost alternative program under section 3; “manufacturer's list price” means the following: (a) in the case of an LCA category having an LCA drug comparator adopted from another jurisdiction under section 3.01 (1) (a) [LCA drug comparators may be adopted from other jurisdictions], the manufacturer's list price per unit of the adopted drug in that jurisdiction; (b) in any other case, the price per unit of a drug, as provided by a manufacturer to the minister in the manner and at the time required by the minister; “maximum accepted list price” means the maximum accepted list price as determined by the minister under section 3 (3); “non-reference drug” means a drug, within a reference drug category, that has not been designated as a reference drug; “oral solid” means a drug that (a) is available in a solid form, including as a gel capsule, chewable tablet or wafer, and (b) is intended to be taken orally; “provisional drug” means a drug designated under section 14 (1) [designation of provisional drugs] as a provisional drug; “reference drug” means a drug, within a reference drug category, designated under section 6 (2) (b) [reference drug program] as a reference drug; “reference drug category” means a category of drugs listed in section 6 (1); “reference drug comparator” means the drug designated under section 6 (2) (c) as the reference drug comparator for a reference drug category. (2) Despite subsection (1), the minister may do one or both of the following for the purposes of the LCA program: (a) deem a generic drug to be a brand drug; (b) deem a brand drug to be a generic drug.
Read the Drug Price Regulation on BC Laws ↗

Made under Pharmaceutical Services Act, SBC 2012, c. 22.